Simple jQuery Dropdowns

Browsing by Author Sai Hong Ignatius Ou

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 3 of 3
Issue DateTitleAuthor(s)
1-Jan-2020An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor–Refractory ALK-Positive or ROS1-Positive NSCLCViola W. Zhu; Yen Ting Lin; Dong Wan Kim; Herbert H. Loong; Misako Nagasaka; Hao To; Yvonne Li En Ang; Chan Young Ock; Nishan Tchekmedyian; Sai Hong Ignatius Ou; Nicholas L. Syn; Thanyanan Reungwetwattana; Chia Chi Lin; Ross A. Soo; National Taiwan University Hospital; Yong Loo Lin School of Medicine; National Taiwan University College of Medicine; Seoul National University Hospital; Wayne State University School of Medicine; National University of Singapore; Faculty of Medicine, Ramathibodi Hospital, Mahidol University; UCI School of Medicine; University of Nevada School of Medicine; Chinese University of Hong Kong; Pacific Shores Medical Group
1-Jan-2015MET exon 14 deletion (METex14): Finally, a frequent-enough actionable oncogenic driver mutation in non-small cell lung cancer to lead MET inhibitors out of "40 years of wilderness" and into a clear path of regulatory approvalThanyanan Reungwetwattana; Sai Hong Ignatius Ou; Mahidol University; UCI School of Medicine
1-Jan-2017The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the InevitableThanyanan Reungwetwattana; Ying Liang; Viola Zhu; Sai Hong Ignatius Ou; Mahidol University; Sun Yat-Sen University Cancer Center; VA Medical Center; UCI Medical Center